{"entity":{"id":"nct06305767","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","aka":["INTerpath-005"],"tldr":"A phase 1/2 trial of Pembrolizumab, Intismeran autogene and Enfortumab vedotin in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) is a phase 1/2 interventional study registered as NCT06305767 by Merck Sharp & Dohme LLC, with 230 participants enrolled, started 2024-03-28 and due to reach its primary completion in 2027-04-23. Interventions recorded: Pembrolizumab, Intismeran autogene, Enfortumab Vedotin and Surgery (RC plus PLND).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06305767","url":"https://clinicaltrials.gov/study/NCT06305767"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":["adc","checkpoint-inhibitor","neoantigen-mrna-vaccine"],"targets":[],"drugs":["pembrolizumab","intismeran-autogene","enfortumab-vedotin"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06305767","phase":"1/2","setting":"A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)","sponsor":"Merck Sharp & Dohme LLC","started":"2024-03-28","startedType":"actual","enrolled":230,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06305767/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}